comparemela.com

Page 9 - ப்ரைம் சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tokyo Stock Exchange: Launch Of JPX English Disclosure GATE

Tokyo Stock Exchange: Launch Of JPX English Disclosure GATE
mondovisione.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondovisione.com Daily Mail and Mail on Sunday newspapers.

Marinomed Biotech AG: Marinomed Biotech AG Leads BCG s Gender Diversity Index Austria 2020

Marinomed Biotech AG: Marinomed Biotech AG Leads BCG s Gender Diversity Index Austria 2020 Korneuburg (pta017/26.02.2021/10:00) - February 26, 2021 Marinomed Biotech AG is Austria s most diverse company regarding gender composition of corporate boards Marinomed scores outstanding 83.4 points on BCG s Gender Diversity Index Austria 2020 Full results published in Austrian economics magazine trend Marinomed Biotech AG (VSE:MARI), a globally operating biopharmaceutical company, announced today that the Company ranks in the first place on Boston Consulting Group s (BCG) Gender Diversity Index Austria 2020 and is officially Austria s most diverse company regarding gender composition of corporate boards. The study focused on the 50 largest public companies in Austria by market capitalization. The results are published in the economics magazine trend.

Под угрозой даже универсам «Центральный» Что происходит в магазинах «Домашний» из-за проблем сети

Под угрозой даже универсам «Центральный» Что происходит в магазинах «Домашний» из-за проблем сети
news.tut.by - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news.tut.by Daily Mail and Mail on Sunday newspapers.

Marinomed Biotech : Leads BCG s Gender Diversity Index Austria 2020

Marinomed Biotech AG , a globally operating biopharmaceutical company, announced today that the Company ranks in the first place on Boston Consulting Group s Gender Diversity Index Austria. | March 4, 2021

Marinomed Biotech AG (via Public) / Marinomed Biotech AG announces positive clinical data for Carragelose lozenges against respiratory viruses including SARS-CoV-2

Marinomed Biotech AG announces positive clinical data for Carragelose lozenges against respiratory viruses including SARS-CoV-2 Marinomed Biotech AG (VSE:MARI), a globally operating biopharmaceutical company, announced today positive results from its clinical study on the antiviral efficacy of Carragelose-containing lozenges (10 mg iota-carrageenan) in 31 healthy subjects. Results show that lozenges provide an additional formulation complementary to Carragelose-based nasal sprays. Both products are available in pharmacies through Marinomed s worldwide distributor network. The clinical study evaluated the inhibition of common human respiratory viruses, namely human Rhinoviruses (HRV) 1a and 8, Coronavirus OC43, Influenza A nH1N1 2009, and Coxsackie virus A10. Additionally, the efficacy against SARS-CoV-2 and human Parainfluenza Virus Type 3 was tested.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.